Biodel Inc. (Nasdaq: BIOD) announced that the following abstracts describing results from studies of the company's product candidates have been accepted for presentation in September during the 46th annual meeting of the European Association for the Study of Diabetes in Stockholm.

Oral Presentation:

#OP 01, Oral session on novel formulations and delivery of insulin, Tuesday, September 21, 2010 10:45 AM - 12:15 PM "A novel pH-neutral formulation of the monomeric insulin VIAject® has a faster onset of action than insulin lispro"; to be presented by Dr. T. Heise, Profil Institut fur Stoffwechselforschung GmbH, Neuss, Germany

Poster Presentations:

#PS 089 Poster session on short-acting insulins, Thursday, September 23, 2010 12:30 PM - 1:30 PM "Biocompatibility of the ultra-rapid insulin VIAject® with continuous insulin infusion sets"; to be presented by Dr. F. Flacke, Biodel, Inc.

#PS 089 Poster session on short-acting insulins, Thursday, September 23, 2010 12:30 PM - 1:30 PM "Pharmacokinetics of novel formulations of insulin analogs that provide a more rapid onset of action in diabetic miniature swine"; to be presented by Dr. R. Pohl, Biodel, Inc.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs. Biodel's new drug application for its most advanced product candidate, VIAject®, has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab™, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon.